GSK
FDA Approves First-in-Class Blujepa to Treat uUTIs in Females 12 and Older
The FDA approved Blujepa to treat female adults (≥40 kg) and children (≥12 years of age, ≥40 kg) with ...
MARCH 26, 2025
FDA Grants Expanded Indication for GSK’s Arexvy
The FDA granted a new indication for GSK’s Arexvy adjuvanted respiratory syncytial virus vaccine to prevent ...
JUNE 13, 2024
ACIP Recommends RSV Vaccine for Adults 60 and Older After Consulting Their Healthcare Providers
The ACIP recently recommended that adults 60 and older may receive one of the new RSV vaccines following a ...
JUNE 26, 2023
FDA Approves First RSV Vaccine in U.S.
The first respiratory syncytial virus (RSV) vaccine, adjuvanted (Arexvy, GSK) has been approved for use in the ...
MAY 4, 2023
Shingles Vaccine Safe, Effective Up to 10 Years Post-Vaccination
The adjuvanted recombinant zoster vaccine (RZV; Shingrix, GSK) for shingles provides long-term protection against ...
DECEMBER 10, 2022
Novel RSV Vaccine Appears Safe in Older Adults
An estimated 1.5 million annual cases of acute respiratory infection from RSV occur in older adults from ...
OCTOBER 24, 2022
FDA Approves Krintafel Single-Dose Malaria Drug
The FDA approved Krintafel, a single-dose medication for the radical cure of Plasmodium vivax malaria in ...
JULY 24, 2018
Tafenoquine Gets FDA Advisory Committee Nod for Approval
The FDA Antimicrobial Drugs Advisory Committee today voted to recommended approval of GSK's tafenoquine for the ...
JULY 12, 2018
CDC’s ACIP Recommends Adding Shingrix to the Adult Vaccination Schedule
The committee voted to include Shingrix (GlaxoSmithKline) in the adult vaccination recommendations for to prevent ...
OCTOBER 26, 2017
FDA Approves Shingrix Shingles Vaccine
Shingrix is a recombinant subunit vaccine given intramuscularly in two doses that combines an antigen, glycoprotein ...
OCTOBER 24, 2017
